TAVR; the potential of Admedus being part of., page-33

Hey B B, just a couple of points;

Value of IP, .... it could be reasonably argued that IP worth should be at least equal to current market cap; book value (low estimate) of 7 mill and up for AI, Adapt IP plus that of TAVR and remainder of MDD worth 30 mill up, some of which is actually revenue producing to the tune of 11 mil.

Given a chance to fund adequately IP should compound in growth and flow on to market cap.

Admedus has very minimal debt, 5 mill has been paid back to SB, 1 mill in hock to SIO in the interim, from that how can SB (or even SIO) walk away with anything of ‘value’??, .....they are right in line with RIs and SIO IF it comes up to divvying up the company, imo.

This company is not Medical Flow which had debt in the tens of millions, that’s where a third party entity ‘walks’ away with all and sundry!

In regards to lengthy suspensions rarely ending up favourably you could ague that in this case that the current suspension is exactly what the company needs; IF it is close to obtaining Funds that are non-dilutive and from a potential upcoming deal.

GLTAH.